Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...
Inventiva participera à quatre conférences investisseurs en mars Daix (France), New York (États-Unis), le 26 février 2026 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que la direction de la Société participera à des réunions individuelles et à des présentations lors des événements investisseurs suivants : TD Cowen 46ème Health Care Conference – 2 au 4 mars 2026Date : lun...
Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2,...
Inventiva to Participate in Four Upcoming March Investor Conferences Daix (France), New York (United States), February 26, 2026 – (Euronext Paris and NASDAQ: ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapie for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in one-on-one meetings and presentations during the following upcoming investor events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026Date: Monday, March 2...
Aalberts: In-line FY25, but low quality / AMG: 4Q25 beat by 7%; in-line 2026 guidance / Bekaert: In-line 2025, cautious outlook for 2026 to result in c.8% consensus cut / CMB.TECH: A small bit beat but not the full story / Corbion: Dividend sweetener / CTP: Q4 results lighter due to some delays; stronger 2026 outlook / DEME: Strong FY25 numbers and FY26 outlook / Elia Group: Preview FY25 results / SBM Offshore: Another step-up in shareholder return / Syensqo: Substantial miss in 4Q25; FY26 outlo...
DEME posted a very solid FY25 with turnover of €4.2bn, broadly in line with expectations, supported by 4% y/y growth in Offshore Energy. Dredging & Infra maintained its record FY24 level at just under €2bn, while Environmental declined 19% y/y to €272m. The order book increased to €7.6bn, benefitting from new awards and the integration of Havfram. FY25 EBITDA rose 22% y/y to a very nice €9 30.5m (KBCSe €871.6m), lifting the margin to 22.4% on strong Offshore Energy performance. Dredging & In...
Full-year results 2025: record performance marks 150 years of delivery Highlights Record results with Group turnover at 4.2 billion euros compared to 4.1 billion euros a year agoEBITDA at 931 million euros from 764 million euros a year ago, an increase of 22%, and reaching 22.4% of turnover, up from 18.6% for 2024Net profit reaching 346 million euros, compared to 288 million euros a year ago, an increase of 20%Proposed gross dividend of 4.5 euros per share, compared to 3.8 euros per share a year ago Order book stood at 7.6 billion euros at the end of the year, above both mid-year and...
Jaarresultaten 2025: recordprestatie zet 150 jaar realisaties in de verf Hoogtepunten Recordresultaten De omzet van de groep bedroeg 4,2 miljard euro, tegenover 4,1 miljard euro een jaar geledenEBITDA was 931 miljoen euro tegenover 764 miljoen euro een jaar geleden, een stijging van 22% met een EBITDA-marge van 22,4%, tegenover 18,6% in 2024De nettowinst was 346 miljoen euro, tegenover 288 miljoen euro een jaar geleden, een stijging van 20%Voorstel voor een brutodividend van 4,5 euro per aandeel, tegenover 3,8 euro een jaar geleden Het orderboek bedroeg aan het einde van het jaar 7,6 milja...
A director at Montea NV bought 1,000 shares at 73.740EUR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
CFE: Preview: underlying 2026 margin to improve / DEME: Preview: strong 2025, eyes on 2026 outlook / JDE Peet's: Acquisition by KDP expected to close in 2Q26 / Solvay: 2025 ends with strong FCF; 2026F und. EBITDA guidance slightly below, supported by one-off / UCB: Peer Moonlake investor day / Vastned: Beat on bottom line with operational metrics accelerating, but outlook remains weak
Below are the highlights from the conference call. We remind that FY25 adjusted EBITDA increased by 11% to 847m, slightly above the high end of the 790-840m guidance range (in line with KBCS estimate, 1% above consensus). The company did not give a precise guidance on FY26 although sounded cautious on developments in the EV industry. The strong metal price environment will partly be offset by lower hedging levels for 2026 and maintenance, while new longer term hedges generate additional earnings...
Ahold Delhaize: Peer Walmart 4Q25/26 results. Arcadis: Main topics 4Q25/FY25 conference call. ASM: 4Q25 preview, FY26 should be strong. Brunel: 4Q25 result beats and trends stabilise; DACH back to growth in 1Q26; additional cost savings announced and special dividend. Cofinimmo: Beat on bottom line, strong investment outlook for 2026. IMCD: Another step in EMEA. Magnum Ice Cream Company: Peer Danone 4Q25 results. Recticel: Peer Kingspan FY25 results. Software sector: Cheaper code...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.